JPMorgan Chase & Co. Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,150.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lowered by JPMorgan Chase & Co. from $1,200.00 to $1,150.00 in a report issued on Thursday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on the stock. Barclays decreased their price target on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating on the stock in a research report on Wednesday. Royal Bank of Canada restated an “outperform” rating and issued a $1,260.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 22nd. Piper Sandler boosted their target price on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating on the stock in a research note on Wednesday, October 16th. Finally, Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,101.00.

Regeneron Pharmaceuticals Trading Up 0.4 %

Shares of Regeneron Pharmaceuticals stock opened at $933.02 on Thursday. The business has a fifty day simple moving average of $1,088.44 and a 200-day simple moving average of $1,040.53. Regeneron Pharmaceuticals has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The firm has a market cap of $102.86 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 3.29 and a beta of 0.12. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. Regeneron Pharmaceuticals’s revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the company earned $8.79 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 37.66 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Wealthcare Advisory Partners LLC lifted its holdings in Regeneron Pharmaceuticals by 14.4% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 37 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 11.6% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 23,151 shares of the biopharmaceutical company’s stock worth $22,283,000 after acquiring an additional 2,412 shares in the last quarter. 180 Wealth Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $218,000. Fifth Third Wealth Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $217,000. Finally, Courier Capital LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $957,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.